Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

[1]  F. Zijlstra,et al.  Thrombus aspiration during primary percutaneous coronary intervention. , 2008, The New England journal of medicine.

[2]  E. Topol,et al.  Facilitated PCI in patients with ST-elevation myocardial infarction. , 2008, The New England journal of medicine.

[3]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[4]  G. Biondi-Zoccai,et al.  Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis , 2008, Heart.

[5]  P. Armstrong,et al.  Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. , 2008, European heart journal.

[6]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[7]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[8]  F. Verheugt,et al.  Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. , 2008, Thrombosis research.

[9]  C. Hamm,et al.  Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  M. Ward,et al.  Field triage to primary angioplasty combined with emergency department bypass reduces treatment delays and is associated with improved outcome. , 2007, European heart journal.

[11]  J. Ottervanger,et al.  Combination of electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty. , 2007, International journal of cardiology.

[12]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[13]  L. Wallentin,et al.  Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. , 2006, JAMA.

[14]  G. Filippatos,et al.  The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. , 2006, European heart journal.

[15]  J. Ottervanger,et al.  Feasibility and benefit of prehospital diagnosis, triage, and therapy by paramedics only in patients who are candidates for primary angioplasty for acute myocardial infarction. , 2006, American Heart Journal.

[16]  J. Boura,et al.  Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials , 2006, The Lancet.

[17]  J. Ottervanger,et al.  Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. , 2005, American heart journal.

[18]  F. Neumann,et al.  Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.

[19]  J. Ottervanger,et al.  Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2004, Journal of the American College of Cardiology.

[20]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[21]  G. Montalescot,et al.  Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. , 2004, JAMA.

[22]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[23]  J. Ottervanger,et al.  Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. , 2004, European heart journal.

[24]  E. Topol,et al.  A preferred reperfusion strategy for acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[25]  Á. Avezum,et al.  Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). , 2003, American heart journal.

[26]  T. Machnig,et al.  Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. , 2003, American heart journal.

[27]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[28]  N. Lakkis,et al.  Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. , 2002, The American journal of cardiology.

[29]  S. de Servi,et al.  Integrated Analysis of Myocardial Blush and ST-Segment Elevation Recovery After Successful Primary Angioplasty: Real-Time Grading of Microvascular Reperfusion and Prediction of Early and Late Recovery of Left Ventricular Function , 2002, Circulation.

[30]  R. Gibbons,et al.  TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging , 2002, Circulation.

[31]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[32]  D. Kereiakes,et al.  Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. , 1999, The American journal of cardiology.

[33]  H. Suryapranata,et al.  Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. , 1998, Circulation.

[34]  Felix Zijlstra,et al.  Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction , 1997, The Lancet.

[35]  R. Califf,et al.  Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. , 1996, The American journal of cardiology.

[36]  R. Califf,et al.  Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. , 1995, Circulation.

[37]  J. Reiber,et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.

[38]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.